- $250.84m
- $234.90m
- $4.41m
Ocugen rises as gene therapy slows vision loss in advanced eye disease trial
Ocugen Q4 net loss widens on higher R&D expenses
Brief: Ocugen Appoints Rita Johnson-Greene To Chief Financial Officer
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Ocugen drops on stock offering
Brief: Ocugen Announces Pricing Of $22.5 Million Offering Of Common Stock
U.S. STOCKS ON THE MOVE-STAAR Surgical, Ocular, Builders FirstSource
U.S. STOCKS ON THE MOVE-Spotify, BlackRock, KLA Corp
Ocugen rises as gene therapy shows promise for blinding eye disease
Brief: Ocugen Announces Positive Preliminary Phase 2 Data From Ocu410 Modifier Gene Therapy For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration
Biotech firm Ocugen's Q3 revenue beats expectations
Brief: Ocugen Inc Says On Sept 16, Carisma Terminates Merger Agreement With Ocugen
U.S. STOCKS ON THE MOVE- Western Alliance Bancorp, CoreWeave, Alphabet
U.S. STOCKS ON THE MOVE-Union Pacific, Corteva, Novocure
U.S. STOCKS ON THE MOVE-Tesla, Ocugen, Union Pacific
Ocugen up after licensing deal for ophthalmic gene therapy in South Korea
Brief: Ocugen Gets EMA Backing on OCU410ST Approval Pathway for Stargardt Gene Therapy
Brief: Ocugen Announces $20 Million Registered Direct Offering Of Common Stock And Warrants